| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000001309 |
| Receipt No. | R000001587 |
| Official scientific title of the study | Prospective clinical study of early diagnosis and treatment for intravasclular large B-cell lymphoma (IVL) |
| Date of disclosure of the study information | 2008/08/11 |
| Last modified on | 2017/08/18 (Ver. 10) |
| Basic information | ||
| Official scientific title of the study | Prospective clinical study of early diagnosis and treatment for intravasclular large B-cell lymphoma (IVL) | |
| Title of the study (Brief title) | Early diagnosis and treatment for IVLBCL | |
| Region |
|
|
| Condition | ||
| Condition | Intravascular large B -cell lymphoma: IVL | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To assess the early clinical diagnosis and treatment of IVLBCL. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | Overall survival |
| Key secondary outcomes | CR rate, Adverse events, Correspondence rate between early clinical diagnosis and pathological diagnosis, Diagnostic rate of bone marrow and/or random skin biopsy, Time to treatment failure |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | 2/3 reduced dose CHOP therapy following rituximab on course 1. Standard dose R-CHOP therapy on course 2 to 6. HDC/AHST if possible. | ||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1, Age more than 19
2, IVL diagnosis 2-1, Pathological diagnosis or 2-2, Early clinical diagnosis who fulfilled our criteria with bone marrow and random skin biopsy 3, Informed consent |
|||
| Key exclusion criteria | 1, collagen vascular disease
2, Severe infectious disease 3, Pre-treatment history for lymphoma 4, HIV+, HTLV1+ or HBV-Ag+ 5, Physician's decision of inappropriateness |
|||
| Target sample size | 10 | |||
| Research contact person | |
| Name of lead principal investigator | Yasufumi Masaki |
| Organization | Kanazawa Medical University |
| Division name | Hematology and Immunology |
| Address | 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa |
| TEL | 076-286-3511 |
| yasum@kanazawa-med.ac.jp | |
| Public contact | |
| Name of contact person | Yasufumi Masaki |
| Organization | Kanazawa Medical University |
| Division name | Hematology and Immunology |
| Address | 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa |
| TEL | 076-286-3511 |
| Homepage URL | http://www.kanazawa-med.ac.jp/~hematol/topics8.html |
| yasum@kanazawa-med.ac.jp | |
| Sponsor | |
| Institute | Department of Hematology and Immunology, Kanazawa Medical University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Department of Hematology and Immunology, Kanazawa Medical University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Hokuriku hematological tumor research group |
| Name of secondary funder(s) | self funding |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 金沢医科大学病院ほか、北陸造血器腫瘍研究会参加施設 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000001587 |